CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
LKB1 mutations have been associated with primary resistance to immune checkpoint inhibitors in patients with lung cancer. Here the authors show that Lkb1-deficient lung tumors are characterized by defective trafficking and adhesion of T cells and that, by upregulating ICAM1 expression, CDK4/6 inhibi...
Main Authors: | Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-36892-4 |
Similar Items
-
Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
by: Kenneth E. Huffman, et al.
Published: (2023-03-01) -
LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
by: Shuang Qu, et al.
Published: (2022-09-01) -
TBC1D23 mediates Golgi-specific LKB1 signaling
by: Yingfeng Tu, et al.
Published: (2024-02-01) -
The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape
by: Guanghui Wang, et al.
Published: (2022-06-01) -
Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice
by: Mei-Jen Hsieh, et al.
Published: (2021-04-01)